Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-02-2016 | Original Article – Cancer Research

Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1

Authors: Koji Numata, Takashi Oshima, Kentaro Sakamaki, Kazue Yoshihara, Toru Aoyama, Tsutomu Hayashi, Takanobu Yamada, Tsutomu Sato, Haruhiko Cho, Manabu Shiozawa, Takaki Yoshikawa, Yasushi Rino, Chikara Kunisaki, Makoto Akaike, Toshio Imada, Munetaka Masuda

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2016

Abstract

Purpose

Curative resection and adjuvant chemotherapy is the standard treatment for Stage II/III gastric cancer, and S-1 is widely used for adjuvant chemotherapy. The type 1 insulin-like growth factor receptor (IGF1R) is involved in cell proliferation and prevention of apoptosis in many tumors. We evaluated the relative expression of the IGF1R gene to determine whether such expression correlates with outcomes in patients with Stage II/III gastric cancer.

Methods

We measured the expression levels of the IGF1R gene in specimens of cancer and adjacent normal mucosa obtained from 134 patients with Stage II/III gastric cancer who received curative resection and adjuvant chemotherapy with S-1. We then evaluated whether the IGF1R gene expression levels correlate with clinicopathological characteristics and outcomes.

Results

IGF1R mRNA expression levels tended to be higher in cancer tissue than in the normal adjacent mucosa (P = 0.078). Multivariate analysis showed that high IGF1R gene expression was a significant independent predictor of poor survival in Stage II/III gastric cancer after curative resection and adjuvant chemotherapy with S-1 (HR 3.681, P = 0.007). The overall survival rate was significantly lower in patients with high IGF1R gene expression than in those with low expression (P = 0.012).

Conclusions

IGF1R overexpression is considered a useful independent predictor of outcomes in Stage II/III gastric cancer after curative resection and adjuvant chemotherapy with S-1.

Adachi Y et al (2009) Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Carcinogenesis 30:1305–1313. doi:10.1093/carcin/bgp134 PubMedCrossRef

Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551PubMedPubMedCentral

Belham C, Wu S, Avruch J (1999) Intracellular signalling: PDK1—a kinase at the hub of things. Curr Biol 9:R93–R96PubMedCrossRef

Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D (1997) Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 152:339–344PubMedCrossRef

Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101–1107PubMedCrossRef

Dallas NA et al (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69:1951–1957. doi:10.1158/0008-5472.CAN-08-2023 PubMedPubMedCentralCrossRef

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687–689PubMedCrossRef

Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262–267PubMedCrossRef

Dudek H et al (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661–665PubMedCrossRef

Ferlay J et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. doi:10.1002/ijc.29210 PubMed

Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3:298–302PubMedCrossRef

Galamb O, Sipos F, Molnar B, Szoke D, Spisak S, Tulassay Z (2007) Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin Cytom 72:299–309. doi:10.1002/cyto.b.20189 PubMedCrossRef

Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158. doi:10.1159/000226089 PubMedCrossRef

Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942–2950PubMed

Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C (2008) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128:1499–1505. doi:10.1038/sj.jid.5701185 PubMedCrossRef

Hopkins A, Crowe PJ, Yang JL (2010) Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136:639–650. doi:10.1007/s00432-010-0792-0 PubMedCrossRef

Imsumran A et al (2007) Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28:947–956. doi:10.1093/carcin/bgl247 PubMedCrossRef

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. doi:10.1038/bmt.2012.244 PubMedPubMedCentralCrossRef

Kharbanda S et al (1997) Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94:6939–6942PubMedPubMedCentralCrossRef

Li H et al (2011) Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 117:3135–3147. doi:10.1002/cncr.25893 PubMedCrossRef

Long L, Rubin R, Baserga R, Brodt P (1995) Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55:1006–1009PubMed

Long L, Rubin R, Brodt P (1998) Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 238:116–121. doi:10.1006/excr.1997.3814 PubMedCrossRef

Ludovini V et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842–849. doi:10.1093/annonc/mdn727 PubMedCrossRef

Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653–3660. doi:10.1210/jcem.85.10.6906 PubMed

Mazumdar M, Smith A, Bacik J (2003) Methods for categorizing a prognostic variable in a multivariable setting. Stat Med 22:559–571. doi:10.1002/sim.1333 PubMedCrossRef

Min KW (2010) Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis. Ultrastruct Pathol 34:174–188. doi:10.3109/01913121003689075 PubMedCrossRef

Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, Kruslin B, Pavelic J (2003) Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 201:430–438. doi:10.1002/path.1465 PubMedCrossRef

Sakuramoto S et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820. doi:10.1056/NEJMoa072252 PubMedCrossRef

Sasako M et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393. doi:10.1200/JCO.2011.36.5908 PubMedCrossRef

Shiraishi T, Mori M, Yamagata M, Haraguchi M, Ueo H, Sugimachi K (1998) Expression of insulin-like growth factor 2 mRNA in human gastric cancer. Int J Oncol 13:519–523PubMed

Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z (1996) Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56:1761–1765PubMed

Valsecchi ME et al (2012) Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 118:3484–3493. doi:10.1002/cncr.26661 PubMedCrossRef

Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095. doi:10.1002/cncr.10945 PubMedCrossRef

Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–628PubMedCrossRef

Title: Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1
Authors: Koji Numata
Takashi Oshima
Kentaro Sakamaki
Kazue Yoshihara
Toru Aoyama
Tsutomu Hayashi
Takanobu Yamada
Tsutomu Sato
Haruhiko Cho
Manabu Shiozawa
Takaki Yoshikawa
Yasushi Rino
Chikara Kunisaki
Makoto Akaike
Toshio Imada
Munetaka Masuda
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2039-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2016

Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts

Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins

Early detection of colorectal cancer: from conventional methods to novel biomarkers

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

Retraction Note to: The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer

Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page